perifosine has been researched along with Cancer of Ovary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y | 1 |
| Hashimoto, K; Hisamatsu, T; Isobe, A; Kawano, M; Kimura, T; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, R; Testa, JR | 1 |
| Dietl, J; Engel, JB; Häusler, S; Honig, A; Horn, E; Köster, F; Krockenberger, M; Schmidt, M; Schönhals, T; Wischhusen, J | 1 |
| Li, J; Sun, H; Yu, T | 1 |
| Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK | 1 |
1 trial(s) available for perifosine and Cancer of Ovary
| Article | Year |
|---|---|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Phosphorylcholine; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids | 2012 |
4 other study(ies) available for perifosine and Cancer of Ovary
| Article | Year |
|---|---|
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA; Signal Transduction | 2013 |
Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Ovarian Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Cisplatin; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2011 |
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Ceramides; Drug Synergism; Female; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |